🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Sickle Cell Kidney Biorepository

Recruitingn/aAges 18 Years - 65 YearsAllUniversity of Texas Southwestern Medical Center
NCT07064174 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age over 18 years, 2. Estimated glomerular filtration rate greater than or equal to 15 mL/min, 3. Presence of any hemoglobinopathy (will need to be confirmed by hemoglobin electrophoresis or genetic testing), 4. Controls (absence of hemoglobinopathy) will be subject to review and only selected if demographics are identical to a currently enrolled participant with a hemoglobinopathy. Exclusion Criteria: 1. Age 66 years or older, 2. Estimated glomerular filtration rate less than 15 mL/min or on dialysis, 3. Active pregnancy (may be enrolled 4 weeks or more after delivery), 4. Active sickle cell pain episode requiring hospitalization or emergency room visit or pain infusion clinic visit (may be enrolled 2 weeks or more after resolution of severe pain), 5. Active malignancy on induction or consolidation treatment. Maintenance chemotherapy in remission will be considered, 6. Prisoners.
💊

What it tests

  • Not listed
📍

Where

2 sites
Parkland Memorial Hospital
Dallas, United States
University of Texas Southwestern Medical Center
Dallas, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy